Impact of Detecting Occult Pathologic Nodal Disease During Resection for Malignant Pleural Mesothelioma
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (4) , e274-e285
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three YearsThe Annals of Thoracic Surgery, 2017
- Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural MesotheliomaAnnals of Surgery, 2014
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility studyThe Lancet Oncology, 2011
- The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the American Joint Committee on Cancer staging systemThe Journal of Thoracic and Cardiovascular Surgery, 2008
- The Value of Occult Disease in Resection Margin and Lymph Node After Extrapleural Pneumonectomy for Malignant MesotheliomaThe Annals of Thoracic Surgery, 2008
- The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 2006
- The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesotheliomaThe Annals of Thoracic Surgery, 2003
- Important prognostic factors in patients with malignant pleural mesothelioma, managed surgicallyThe Annals of Thoracic Surgery, 1999
- Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patientsThe Journal of Thoracic and Cardiovascular Surgery, 1999
- Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.Journal of Clinical Oncology, 1993